Complexity of predicting the magnitude of drug-drug interactions in an individual patient: This cannot fit to a pocket guide; ipad may be!  by Rostami-Hodjegan, A.
Clinical Therapeutics
e126 Volume 35 Number 8S
TargeTS for drug deVelopmeNT  
iN HiV NeuropaTHy
A.S.C. Rice*
Pain Research, Imperial College, London, United Kingdom
Summary: There are globally ~34 million people infected with HIV. 
About 40% of those people living with HIV, whose infection is sup-
pressed by antiretroviral therapy (ART) and are often otherwise well, 
have a length-dependent distal symmetrical sensory polyneuropathy, 
which in most cases is associated with neuropathic pain. This makes 
sensory neuropathy 1 of the most prevalent clinical manifestations 
of HIV in the current era of combined ART and therefore an increas-
ingly major area of therapeutic need. Sensory neuropathy is usu-
ally attributable to either viral–neuronal interactions and/or ART 
neurotoxicity.
Data will be reviewed for:
-  the epidemiologic and risk factors of HIV-associated neuropathy
-  efficacy of current therapies: a meta-analysis of current rand-
omized controlled trials for neuropathic pain in HIV
-  sensory profiles and other clinical characteristics in HIV-positive 
patients with and without sensory neuropathy
-  laboratory animal modeling of HIV GP120-induced neuropa-
thy, including ethologically relevant complex pain behaviors and 
pharmacologic analysis
-  laboratory animal modeling of ART neurotoxicity, including 
ethologically relevant complex pain behaviors and pharmaco-
logic analysis
-  use of gene microarray studies of animals models to reveal novel 
drug targets
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updaTe oN THe STaTuS of arTemiSiNiN 
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Summary: Drug Resistance and Containment Unit, Global Malaria 
Programme, World Health Organization, Geneva, Switzerland.
Global malaria control has been threatened by resistance to 
antimalarial medicines. P falciparum resistance to chloroquine and 
pyrimethamine both originated in Southeast Asia and subsequently 
spread to Africa with substantial implications for global public health. 
Similarly, in the 1980s, resistance to mefloquine emerged rapidly on 
the western border of Cambodia and on the northwest border of 
Thailand only a few years after its introduction. In April 2001, WHO 
recommended the use of artemisinin-based combination therapies 
(ACTs), combining an artemisinin derivative, known for its rapid 
action and short elimination from the body, with another drug char-
acterized by a different mechanism of action and slow elimination.
Emerging P falciparum resistance to artemisinin derivatives is 
a major global public health concern. WHO first issued a warning 
about the threat of artemisinin resistance in the Greater Mekong sub-
region in 2005, after routine efficacy studies showed delayed clear-
ance after ACTs. The first cases of confirmed artemisinin resistance 
were found in western Cambodia, along the Cambodia–Thailand 
border in late 2006. The 4 countries most affected by the emergence 
of artemisinin resistance are Cambodia, Myanmar, Thailand, and 
Vietnam. Despite observed changes in parasite sensitivity to arte-
misinins, ACTs continue to cure patients, provided the partner drug 
is efficacious. However, once resistance to artemisinin emerges, it is 
more likely that resistance to the partner drug will also develop and 
vice versa. Currently and in absence of a molecular marker, the best 
available indicator of suspected artemisinin resistance is the propor-
tion of patients who are still parasitemic at day 3 (72 hours) after a 
full course of an ACT.
In 2010, WHO developed the Global Plan for Artemisinin 
Resistance Containment (GPARC). The plan was drafted after a con-
sultation with all constituencies of the Roll Back Malaria Partnership, 
as well as a range of donor organizations and industry partners. 
WHO is also currently implementing an emergency response plan 
to scale-up efforts to contain artemisinin resistance in the Greater 
Mekong subregion. The presentation will provide an update of the 
current status of artemsinin resistance and containment activities.
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uNdergraduaTe TraiNiNg for mediCal 
STudeNTS iN CpT aNd preSCribiNg
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Summary: Prescribing is a complex task and is often undertaken 
by the most inexperienced doctors. From day 1, new doctors need 
to be able to prescribe safely and rationally. It is clear that this 
requires more than traditional textbook knowledge of pharmacology. 
Preparing new graduates to be effective prescribers is 1 of the major 
concerns of modern undergraduate medical education. Evidence sug-
gests that this training could be improved, although there is debate 
about the most effective methods for doing so.
This presentation will review the perceived deficiencies of current 
teaching, the challenges of delivering effective prescribing education, 
and the available evidence on a range of teaching and learning meth-
ods. In particular, the UK British Pharmacological Society 2012 rec-
ommendations for undergraduate education in clinical pharmacology 
and therapeutics will be used as an example of how medical educators 
might approach this difficult area.
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ComplexiTy of prediCTiNg THe magNiTude 
of drug-drug iNTeraCTioNS iN aN 
iNdiVidual paTieNT: THiS CaNNoT fiT To a 
poCkeT guide; ipad may be!
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Manchester, Manchester, United Kingdom
Summary: The increased prominence of in vitro–in vivo extrapola-
tion (IVIVE) capabilities has helped with recognizing the potential of 
drug–drug interactions (DDI) at early stages of drug discovery. Latest 
regulatory guidelines by the EMA and FDA provide recommenda-
tions for conduct of IVIVE through modeling. They are designed to 
protect the public from adverse effects associated with likely DDI 
by appropriate labeling or preventing the marketing of drugs with 
unmanageable DDI. However, DDI in an individual patient are deter-
mined by a myriad of variables. Prescribers may use labels in the 
clinical practice; nonetheless, currently, labels do not provide infor-
mation for all the different permutation of conditions that put certain 
subgroup of patients at higher risk (eg, comorbid diseases, genetics, 
age and intake of several drugs). Some recent attempts by both the 
FDA and EMA have moved the focus from an average individual to 
a perceived susceptible patient (eg, chronic renal failure).
Creation of user-friendly interface computer programs of DDI 
prediction, which takes the sources of variability into account, may 
assist with the prediction and management of DDI in an individual 
patient. The required information on drugs (ie, affinity to various 
enzymes, nonenzymatic routes, permeability, protein binding, inhibi-
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tory potency) can be retrieved from libraries within the simulator. 
However, the information on each patient (ie, demography, physi-
ology, genetics, enzyme abundances and activity, level of plasma 
proteins, kidney function, various drugs taken and their dosage 
information) are also required. Some of these are not available rou-
tinely and hold the key to “Clinical Oriented” applications (eg, in 
iPad and so on).
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deVelopiNg a STaNdardiSed preSCripTioN 
CHarT To reduCe error
P. Routledge*
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Cardiff, United Kingdom
Summary: Unfamiliarity is an important contributor to error, includ-
ing medication errors, some of which result in adverse events. Paper-
based inpatient prescription charts differ in different hospitals, and 
medical trainees move around health care systems, so they may be 
unfamiliar with such charts initially.
Standards for the design of inpatient prescriptions charts have 
recently been agreed by the Academy of Medical Royal Colleges 
in the United Kingdom.1 In several studies, standardization of pre-
scribing documents has been associated with significantly reduced 
medication errors in adults in Australia,2 as well as in some aspects of 
pediatric medicine. The introduction of a single inpatient prescription 
chart in Wales in 20043 and its subsequent continuing development 
will be described. The training resources developed to support the 
chart will also be discussed.
Standardization of prescribing standards, of acceptable abbrevia-
tions, and standardized training in prescribing can also all contribute 
to a reduction in medication errors and associated adverse events, 
including when electronic rather than paper-based prescriptions are 
written.
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THe iNdiVidualiSaTioN of CaNCer THerapy 
iN orgaN dySfuNCTioN
M. Rudek*
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Summary: Cancer patients with adequate hepatic or renal func-
tion are typically studied during drug development. The majority 
of anticancer agents are cleared by via hepatic or renal mechanisms. 
Therefore, dose adjustments would be anticipated in patients with 
organ dysfunction. However, when a drug is approved, dosing modi-
fication guidelines are often lacking for patients who have varying 
degrees of hepatic or renal dysfunction, especially moderate or severe 
dysfunction. In clinical practice, oncologists may start therapy with 
an empirically derived lower starting dose due to the perception that 
a patient with organ dysfunction would have poorer tolerability 
due to increased toxicity. The presentation will summarize: (1) A 
brief historical perspective of individualization of cancer therapy 
in organ dysfunction; (2) pathophysiology of organ dysfunction in 
cancer patients; (3) barriers to the conduct of clinical trials in this 
population; and (4) recent examples of dosing recommendations for 
anticancer agents.
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Summary: In addition to the increasing number of biological and 
biotechnological medicinal products available for different clinical 
indications, the development of gene- and cell-based products offer 
alternative approaches for the prevention and treatment of human 
diseases. An increasing number of gene therapy and somatic cell ther-
apy products are already in clinical development for the treatment 
of inherited diseases, cancer, diabetes, Parkinson’s disease, and other 
neurodegenerative disorders. As gene and cell therapy products are 
presented as having properties for treating or preventing diseases in 
human beings, or that they may be used in or administered to human 
beings with a view to restoring, correcting, or modifying physiologi-
cal functions by exerting principally a pharmacologic, immunologic, 
or metabolic action, they are considered biological medicinal prod-
ucts within the meaning of Annex I to Directive 2001/83/EC of the 
European Parliament and of the Council of 6 November 2001 on 
the Community code relating to medicinal products for human use.
Regulation (EC) 1394/2007 introduces additional provisions to 
those laid down in Directive 2001/83/EC and regulates advanced 
therapies that are intended to be placed on the market in the EU 
Member States and either prepared industrially or manufactured by 
a method involving an industrial process. However, ATMP “prepared 
on a non-routine basis according to specific quality standards, and 
used within the same Member State in a hospital under the exclu-
sive professional responsibility of a medical practitioner, in order to 
comply with an individual medical prescription for a custom-made 
product for an individual patient” are excluded. EU Member States 
are currently developing the rules to apply to these products to guar-
antee their quality and safety.
A review of gene therapy medicinal products that have applied 
for marketing authorization application through the European 
Medicines Agency will be presented.
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dopiNg iN SporT: THe biomarkerS are THe 
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Summary: The athlete biological passport (ABP) is an individual and 
longitudinal monitoring of biomarkers potentially linked to doping. 
